A Phase 1/2 Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
Latest Information Update: 21 Sep 2023
At a glance
- Drugs VGB-R04 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Shanghai Vitalgen BioPharma
- 06 Jul 2022 New trial record